Hippocampal and Thalamic DBS for Bilateral Temporal Lobe Epilepsy
Hippocampal and Thalamic DBS for Bilateral Temporal Lobe Epilepsy
The study aims to compare the safety and effectiveness of deep brain stimulation of the
 hippocampus and the anterior nucleus of the thalamus for reducing the frequency of seizures
 in patients with bilateral temporal lobe epilepsy.
The outcome of resective surgery for bilateral temporal lobe epilepsy (BTLE) is poor.
 Neuromodulation such as deep brain stimulation is an alternative therapy for patients with
 drug-resistant epilepsy, especially for those not suitable for resective surgery. This
 prospective, randomized, open-label trial aims to compare the effectiveness of deep brain
 stimulation of the hippocampus and the anterior nucleus of the thalamus for bilateral
 temporal lobe epilepsy.
Inclusion Criteria:

 1. Patients between 12 to 60 years old.

 2. Bilateral temporal lobe epilepsy patients proved by VEEG or SEEG.

 3. At least 3 seizures per month but not more than 10 seizures per month, and the longest
 seizure interval is no more than 30 days during the baseline.

 4. Patients failed to at least 3 antiepileptic drugs (AEDs), and are receiving at least 1
 AEDs now.

 5. Be able to complete seizure diary.

 6. Agree to participate this study and sign informed consent.

 Exclusion Criteria:

 1. Extratemporal lobe epilepsy or with potential extratemporal epileptogenic focus.

 2. Patients with psychogenic non-epileptic seizures.

 3. IQ < 70, or unable to complete the study.

 4. Patients are pregnant or plan for it.

 5. Patients with implanted electrical stimulation medical device.

 6. Patients with other severe neuropsychiatric disorders such as dementia, schizophrenia,
 or neurodegenerative diseases.

 7. Patients with cerebral lesions which unsuitable for lead implantation.